(Q44229660)

English

The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

0 references

1 reference

based on heuristic

inferred from title

2

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

author name string

A K Burnett

1

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

A E Hunter

3

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

D Milligan

4

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

W J Kell

5

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

K Wheatley

6

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

J Yin

7

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

M F McMullin

8

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

H Dignum

9

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

D Bowen

10

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

N H Russell

11

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

UK National Cancer Research Institute AML Working Group

12

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

publication date

14 August 2012

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

27

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

75-81

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.229

21 January 2018

A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.229

21 January 2018

Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.229

21 January 2018

Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.229

21 January 2018

Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.229

21 January 2018

On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.229

21 January 2018

The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.229

21 January 2018

Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.229

21 January 2018

European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.229

21 January 2018

Applicability of a "Pick a Winner" trial design to acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.229

21 January 2018

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.229

21 January 2018

Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin).

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.229

21 January 2018

Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.229

21 January 2018

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.229

21 January 2018

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.229

21 January 2018

Phase I study of temozolomide and laromustine (VNP40101M) in patients with relapsed or refractory leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.229

21 January 2018

Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.229

21 January 2018

Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.229

21 January 2018

Anthracycline dose intensification in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.229

21 January 2018

High-dose daunorubicin in older patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.229

21 January 2018

The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.229

7 January 2021

based on heuristic

inferred from DOI database lookup

A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.229

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.229

7 January 2021

based on heuristic

inferred from DOI database lookup

Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.229

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/LEU.2012.229

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44229660&oldid=2206513144"